These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 25869576)
1. Preanalytical variables and Alzheimer disease biomarker concentrations in cerebrospinal fluid. Florkowski CM Clin Chem; 2015 May; 61(5):686-8. PubMed ID: 25869576 [No Abstract] [Full Text] [Related]
2. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Le Bastard N; De Deyn PP; Engelborghs S Clin Chem; 2015 May; 61(5):734-43. PubMed ID: 25869575 [TBL] [Abstract][Full Text] [Related]
3. Alzheimer disease: Cerebrospinal fluid markers for AD change during middle age. Chase A Nat Rev Neurol; 2015 Aug; 11(8):427. PubMed ID: 26215625 [No Abstract] [Full Text] [Related]
4. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid opens a window on Alzheimer disease. Galasko D Arch Neurol; 1999 Jun; 56(6):655-6. PubMed ID: 10369301 [No Abstract] [Full Text] [Related]
6. Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease. Verbeek MM; Olde Rikkert MG Clin Chem; 2008 Oct; 54(10):1589-91. PubMed ID: 18824570 [No Abstract] [Full Text] [Related]
7. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Vanderstichele H; Bibl M; Engelborghs S; Le Bastard N; Lewczuk P; Molinuevo JL; Parnetti L; Perret-Liaudet A; Shaw LM; Teunissen C; Wouters D; Blennow K Alzheimers Dement; 2012 Jan; 8(1):65-73. PubMed ID: 22047631 [TBL] [Abstract][Full Text] [Related]
8. Alzheimer's Disease Biomarker Profile in Cerebrospinal Fluid of Individuals with Immune-Mediated Encephalitis. Fernandez Suarez M; Surace EI; Riudavets M; Nogues M; Vazquez S; Sevlever G; Allegri RF J Am Geriatr Soc; 2016 Sep; 64(9):e29-31. PubMed ID: 27550068 [No Abstract] [Full Text] [Related]
9. From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. Zetterberg H; Blennow K J Alzheimers Dis; 2018; 64(s1):S271-S279. PubMed ID: 29758941 [TBL] [Abstract][Full Text] [Related]
10. Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker. Holtzman DM JAMA; 2010 Nov; 304(17):1887. PubMed ID: 21045090 [No Abstract] [Full Text] [Related]
11. Multiplex method for measuring biomarkers of Alzheimer disease in cerebrospinal fluid. Miller BB; Mandell JW Clin Chem; 2005 Feb; 51(2):289-90. PubMed ID: 15681556 [No Abstract] [Full Text] [Related]
13. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Brinkmalm A; Brinkmalm G; Honer WG; Frölich L; Hausner L; Minthon L; Hansson O; Wallin A; Zetterberg H; Blennow K; Öhrfelt A Mol Neurodegener; 2014 Nov; 9():53. PubMed ID: 25418885 [TBL] [Abstract][Full Text] [Related]
14. What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis? Hirtz C; Lehmann S Bioanalysis; 2015; 7(22):2849-51. PubMed ID: 26600059 [No Abstract] [Full Text] [Related]
15. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. Szalárdy L; Zádori D; Klivényi P; Vécsei L J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812 [TBL] [Abstract][Full Text] [Related]